ReviewPulmonary therapy2023
Early Diagnosis and Treatment of Idiopathic Pulmonary Fibrosis: A Narrative Review.
Review in Pulmonary therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Impact of time to diagnosis in patients with progressive fibrotic ILD: a systematic review.BMJ open respiratory research · 2026Pooled it
- Association Between DLCO and Echocardiographic Right Ventricular-Pulmonary Arterial Coupling in Idiopathic Pulmonary Fibrosis.Journal of clinical medicine · 2026Article
- A Nomogram Model for Early Mortality Risk Stratification in Elderly Patients with Idiopathic Pulmonary Fibrosis: An Integrative Analysis of Serum Biomarkers and Pulmonary Function Parameters.Journal of clinical medicine · 2026Article
- Targeting mTORC1/TGFB1 signaling with a novel Bergapten-Esculetin combination: a computational and experimental approach in idiopathic pulmonary fibrosis.Molecular diversity · 2026Article
- Quzhou Aurantii Fructus Extract Attenuates Idiopathic Pulmonary Fibrosis by Regulating Nrf2/HO-1 Axis.Biology · 2026Article
- Senescent fibroblasts in aging and pulmonary fibrosis.Frontiers in aging · 2026Review
- Efficacy and safety of nintedanib combined with pirfenidone versus monotherapy in patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis.American journal of translational research · 2026Review
- Spatiotemporal Immune-Fibroblast Crosstalk in Pulmonary Fibrosis: From Failed Repair to Fibrotic Niche Formation.International journal of biological sciences · 2026Review
- Retrospective analysis of the clinical features and prognosis of idiopathic pulmonary fibrosis combined with lung cancer.BMC cancer · 2025Article
- A supported decision-making model for idiopathic pulmonary fibrosis based on feature screening and optimized neural network.Scientific reports · 2025Article
- The benefits of a rapid diagnostic primary care circuit for interstitial lung disease.NPJ primary care respiratory medicine · 2025Article
- Hesperetin Alleviates Bleomycin-Induced Pulmonary Fibrosis by Modulating Cellular Senescence and Promoting Impaired Autophagy in a CISD2-Dependent Manner.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025Article
- AI-Based HRCT Quantification in Connective Tissue Disease-Associated Interstitial Lung Disease.Diagnostics (Basel, Switzerland) · 2025Article
- A Microemulsion for Oral Delivery of Nintedanib - QbD-Enabled Formulation Development, In-Vitro Characterization & In-Vivo Pharmacokinetic Assessment.The AAPS journal · 2025Article
- [Pirfenidone inhibits bladder cancer xenograft growth in mice by regulating regulatory T cells].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2025Article
- Diagnosis of early idiopathic pulmonary fibrosis: current status and future perspective.Respiratory research · 2025Review
- Insight into the efficacy and safety of pirfenidone: The treatment of idiopathic pulmonary fibrosis.World journal of clinical cases · 2025Article
- Context-Driven Active Contour (CDAC): A Novel Medical Image Segmentation Method Based on Active Contour and Contextual Understanding.Sensors (Basel, Switzerland) · 2025Article
- Widening Patient Engagement for Rare Disease Drug Trials: The Perspectives of Patients With Idiopathic Pulmonary Fibrosis on Participating in Clinical Drug Trials and Drug Trial Design.Health expectations : an international journal of public participation in health care and health policy · 2025Article
- CD206 and dust particles are prognostic biomarkers of progressive fibrosing interstitial lung disease associated with air pollutant exposure.Scientific reports · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive fibrosing interstitial lung disease of unknown aetiology. Patients typically present with symptoms of chronic dyspnoea and cough over a period of months to years. IPF has a poor prognosis, with an average life expectancy of 3-5 years from diagnosis if left untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been approved for the treatment of IPF. These drugs slow disease progression by reducing decline in lung function. Early diagnosis is crucial to ensure timely treatment selection and improve outcomes. High-resolution computed tomography (HRCT) plays a major role in the diagnosis of IPF. In this narrative review, we discuss the importance of early diagnosis, awareness among primary care physicians, lung cancer screening programmes and early IPF detection, and barriers to accessing anti-fibrotic medications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.